α1-antitrypsin deficiency: Memorandum from a WHO meeting

Bulletin of the World Health Organization

Volumn 75, Issue 5, 1997, Pages 397-415

  Boulyjenkov, V ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN DEFICIENCY; CAUSE OF DEATH; CHOLESTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CYSTIC FIBROSIS; DISEASE ASSOCIATION; EUROPE; GENE FREQUENCY; GENE LOCUS; HUMAN; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LUNG EMPHYSEMA; NORTH AMERICA; SWITZERLAND; WORLD HEALTH ORGANIZATION;

ADULT; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MULTICENTER STUDIES; PANCREATIC ELASTASE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TRYPSIN INHIBITORS; WORLD HEALTH ORGANIZATION;

EID: 2642680855     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (81)

1. 1-antitrypsin deficiency. Scandinavian journal of clinical and laboratory investigation, 1963, 15: 132-140.
2. 1-antitrypsin deficiency. Acta medica scandinavica, 1965, 432: 1-85.
3. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annual review of biochemistry. 1983. 52: 355-409.
4. Carrell RW, Boswell DR. Serpins: the superfamily of plasma serine proteinase inhibitors. In: Barrett A, Salvesen G, eds. Proteinase inhibitors. Amsterdam, Elsevier Biomedical Press, 1986: 403-419.
5. Potempa J, Korzus E, Travis J. The serpin family of proteinase inhibitors: structure, function and regulation. Journal of biological chemistry. 1994, 269: 15957-15960.
6. 1-antitrypsin for structure and function of serpins. Biochemistry, 1989, 28: 8951-8966.
7. Engh RA et al. Divining the serpin inhibition mechanism: a suicide substrate "springe"? Trends in biotechnology, 1995, B: 503-510.
8. Carrell RW, Stein PE. The biostructural pathology of the serpins. Biological chemistry, Hoppe-Seyler, 1996, 377: 1-17.
9. Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease? Nature structural biology, 1995, 2: 96-114.
10. 1-antitrypsin. Nature, 1982, 298: 329-334.
11. 1-antitrypsin PiZ. FEBS letters, 1976, 65: 195-197.
12. 1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency. Proceedings of the National Academy of Sciences of the USA, 1976, 73: 1324-1328.
13. 39ÆCys). Human genetics, 1989, 84: 55-58.
14. 1-antitrypsin. American journal of human genetics, 1989, 44: 894-902.
15. iiyama (Serine53 (TCC) to phenylalanine 53 (TCC)). Journal of biological chemistry, 1991, 266: 12627-12632.
16. 1-antitrypsin causes a protein folding defect. Nature structural biology, 1995, 2: 363-367.
17. 1-antitrypsin variant. Journal of biological chemistry, 1990, 265: 14001-14007.
18. 1-antitrypsin accumulation in the liver. Nature, 1992, 357: 605-607.
19. 53ÆPhe): further evidence for intracellular loop-sheet polymerisation. Journal of biological chemistry. 1993, 268: 15333-15335.
20. 1-Antitrypsin deficiency. In: Scriver CR et al., eds. The metabolic and molecular bases of inherited disease, 7th ed. New York, McGraw-Hill, 1995: 4125-4158.
21. 1-antitrypsin deficiency and related disorders. In: Emery AEH, Rimolin DL, eds. Principles and practice of medical genetics, vol. 2. New York, Churchill Livingstone, 1983: 911-935.
22. 1-proteinase inhibitor protein. Disease markers. 1985, 3: 135.
23. 1-antitrypsin deficiency detected by screening of 200 000 infants. New England journal of medicine, 1976, 294: 1316-1321.
24. 1-antitrypsin: electrophoretic variation and DNA haplotypes. American journal of human genetics, 1989, 44: 844-854.
25. 1-antitrypsin associated with deficiency. In: Allen RC, Arnaud P, eds. Proceedings of the Third International Conference on Electrophoresis, 1981, New York. New York, de Gruyter, 1981: 505-510.
26. 1-antitrypsin gene. American journal of human genetics, 1987, 41: 891-906.
27. 1 antitrypsin gene in normal subjects and in patients with pulmonary emphysema. Journal of medical genetics, 1987, 24: 47-51.
28. 1-antitrypsin indicate a single origin for deficiency allele PIZ. Nature, 1985, 316: 79-81.
29. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency. American journal of medicine, 1988, 84 (suppl. 6A): 13-31.
30. Brantly ML et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. American review of respiratory disease, 1988, 138: 327-336.
31. Gishen P et al. Alpha-1-antitrypsin deficiency: the radiological features of pulmonary emphysema in subjects of PI-type Z and PI-type SZ: a survey by the British Thoracic Association. Clinical radiology, 1982, 33: 371-377.
32. Wall M et al. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. Journal of pediatrics, 1990, 116: 248-251.
33. 1-antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi Type Z. British journal of disease of the chest, 1983, 77: 14-27.
34. Janus ED, Phillips NT, Carrell RW. Smoking lung function, and alpha-1-antitrypsin deficiency. Lancet, 1985, 1: 152-154.
35. The Alpha-1-Antitrypsin Deficiency Registry Study Group. A registry of patients with severe deficiency of alpha-1-antitrypsin: design and methods. Chest, 1994, 106: 1223-1233.
36. 1-antitrypsin deficiency, PiZ. Acta medica scandinavica, 1978, 204: 345-351.
37. Eriksson S. Studies in alpha-1-antitrypsin deficiency. Acta medica scandinavica, 1965, 177: 1-85.
38. Waller RE. Field investigations of air. In: Holland WW et al., eds. Oxford textbook of public health, vol. 2, 2nd edit. Oxford, Oxford University Press, 1991: 435-450.
39. Abbey DE et al. Estimated long-term ambient concentrations of PM10 and development of respiratory symptoms in a nonsmoking population. Archives of environmental health, 1995, 50: 139-152.
40. Schwartz J. Air pollution and hospital admissions for the elderly in Detroit, Michigan. American journal of respiratory and critical care medicine, 1995, 150: 648-655.
41. Bakke PS et al. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax, 1991, 46: 863-870.
42. Shaheen SO et al. The relationship between pneumonia in early childhood and impaired lung function in late adult life. American journal of respiratory and critical care medicine. 1994, 149: 616-619.
43. Shaheen SO et al. Do lower respiratory tract infections in early childhood cause chronic obstructive pulmonary disease? American journal of respiratory and critical care medicine, 1995, 151: 1649-1652.
44. Silverman EK et al. Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. American review of respiratory disease, 1989, 140: 961-966.
45. Monso E et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. American journal of respiratory and critical care medicine, 1995, 152: 1316-1320.
46. Silverman EK et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: residual family resemblance beyond the effect of the Pi locus. Human heredity, 1990, 40: 340-355.
47. Wright JL et al. Airway inflammation and peribronchiolar attachments in the lungs of nonsmokers, current and ex-smokers. Lung, 1988, 166: 277-286.
48. Snider GL. Emphysema: the first two centuries- and beyond; a historical overview, with suggestions for future research: part 2. American review of respiratory disease, 1992, 146: 1615-1622.
49. Stockley RA et al. Elastase inhibitors of sputum sol phase: variability, relationship to neutrophil elastase inhibition, and effect of corticosteroid treatment. Thorax, 1986, 41: 442-447.
50. Shin MS, Ho K-J. Bronchiectasis in patients with alpha-1-antitrypsin deficiency: a rare occurrence? Chest, 1993, 104: 1384-1386.
51. Seersholm N, Kok-Jensen A. Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha-1-antitrypsin deficiency. American journal of respiratory and critical care medicine, 1995, 151: 369-373.
52. 1-antitrypsin deficiency with special reference to non-index cases. Thorax, 1994, 49: 695-698.
53. Lieberman J, Winter B, Sastre A. Alpha-1-antitrypsin PI-types in 965 COPD patients. Chest, 1986, 89: 370-373.
54. Stoller JK et al. Physical and social impact of alpha-1-antitrypsin deficiency: results of a mail survey of the readership of a national newsletter. Cleveland Clinic journal of medicine, 1995, 61: 461-467.
55. 1-antitrypsin deficiency: a previously unrecognized inherited disorder. Journal of laboratory and clinical medicine, 1969, 73: 934-939.
56. 1-antitrypsin deficiency. New England journal of medicine, 1972, 287: 1264-1267.
57. 1-antitrypsin deficiency. American journal of medicine, 1983, 74: 221-227.
58. Propst T et al. Prevalence of hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Journal of hepatology, 1994, 21: 1006-1011.
59. 1-antitrypsin deficiency. New England journal of medicine, 1986, 314: 736-739.
60. 1-antitrypsin deficiency and chronic liver disease. Annals of internal medicine, 1992, 117: 641-645.
61. Edmonds BK, Hodge JA, Rietschel RL. Alpha-1-antitrypsin deficiency-associated panniculitis: Case report and review of the literature. Pediatric dermatology, 1991, 8: 296-299.
62. 1-antitrypsin experience. Thorax, 1988, 43: 505-507.
63. Hubbard RC et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha-1-antitrypsin deficiency. Journal of the American Medical Association, 1988, 260: 1259-1264.
64. 1-antitrypsin deficiency. Chest, 1994, 106: 651-652.
65. 1-antitrypsin: Journal of applied physiology, 1987, 63: 2015.
66. 1-PI deficiency: comparison of 161 untreated Danish and 235 German patients receiving augmentation therapy. American journal of respiratory and critical care medicine, 1995, 151: A835.
67. Boris-Lawrie KA, Temin HM. Recent advances in retrovirus technology. Current opinion in genetic development, 1993, 301: 353-362.
68. 1-antitrypsin gene in vivo. Science, 1987, 237: 762-764.
69. Kolodka TM, Finegold M, Woo SLC. Hepatic gene therapy: efficient retroviral-mediated gene transfer into rat hepatocytes in vivo. Somatic cell and molecular genetics, 1993, 19: 491-497.
70. 1-antitrypsin delivery. Clinical research, 1989, 37: 578A.
71. Strauss SE. In: Ginsberg H, ed. The adenoviruses. New York. Plenum Press, 1984: 451-496.
72. Jaffe HA et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nature genetics. 1992, 1: 368-371.
73. 1-antitrypsin gene to lungs of rabbits. American journal of respiratory cell and molecular biology. 1994, 10: 24-29.
74. Michael SI, Curiel DT. Strategies to achieve targetted gene delivery via the receptor-mediated endocytosis pathway. Gene therapy, 1994, 1: 223-232.
75. 1-antitrypsin by electrofocusing. Clinical chemistry, 1982, 28: 219-225.
76. 1-antitrypsin followed by phenotyping of deficient specimens by isoelectric focusing. Screening, 1994, 3: 23-31.
77. 1-Antitrypsin deficiency: a need for screening? Screening, 1992, 1: 195-201.
78. 1-antitrypsin deficiency. Hepatology, 1995, 22: 514-517.
79. Hutchison DCS et al. Longitudinal studies in alpha-1-antitrypsin deficiency: a survey by the British Thoracic Society. In Taylor JC, Mittman C, eds. Pulmonary emphysema and proteolysis. New York, Academic Press, 1987: 7-15.
80. Wu MC, Eriksson S. Lung function, smoking, and survival in severe alpha-1-antitrypsin deficiency, PI*ZZ. Journal of clinical epidemiology, 1988, 41: 1157-1165.
81. Buist AS et al. The natural history of air-flow obstruction in PiZ emphysema. American review of respiratory disease, 1983, 127 (suppl): S43-S50.